These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2141006)

  • 1. A synthetic thymic hormone, THF-gamma 2, repairs immunodeficiency of mice cured of plasmacytoma by melphalan.
    Ophir R; Pecht M; Rashid G; Halperin D; Lourie S; Burstein Y; Ben-Efraim S; Trainin N
    Int J Cancer; 1990 Jun; 45(6):1190-4. PubMed ID: 2141006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. THF-gamma 2, a synthetic thymic hormone, increases effectiveness of combined chemotherapy and immunotherapy against RPC-5 murine plasmacytoma.
    Ophir R; Pecht M; Relyveld EH; Burstein Y; Ben-Efraim S; Trainin N
    Int J Immunopharmacol; 1990; 12(7):751-4. PubMed ID: 2292455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-gamma 2 in combination with an "immunomodulating" or a "non-immunomodulating" drug.
    Ophir R; Pecht M; Burstein Y; Harshemesh H; Ben-Efraim S; Trainin N
    Int J Cancer; 1991 Apr; 48(1):96-100. PubMed ID: 2019463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
    Mokyr MB; Bartik MM; Ahn MC
    Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
    Mokyr MB; Barker E
    Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy.
    Bartik MM; Ahn MC; Baumgartel BA; Hendricks RL; Mokyr MB
    Cancer Immunol Immunother; 1990; 32(3):143-53. PubMed ID: 2289208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy.
    Shoval S; Ophir R; Ben-Efraim S
    Cancer Immunol Immunother; 1989; 29(4):279-87. PubMed ID: 2787695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy.
    Ophir R; Pecht M; Keisari Y; Rashid G; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y
    Immunopharmacol Immunotoxicol; 1996 May; 18(2):209-36. PubMed ID: 8771368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
    Adler A; Keisari Y; Ofir R
    J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E; Wise JA; Dray S; Mokyr MB
    Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of murine Lewis lung carcinoma metastases by combined chemotherapy and intranasal THF-gamma 2 immunotherapy.
    Rashid G; Ophir R; Pecht M; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y; Keisari Y
    J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):324-33. PubMed ID: 8941872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
    Barker E; Mokyr MB
    Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.
    Bartik MM; Baumgartel-Scofield BA; Mokyr MB
    Cancer Immunol Immunother; 1991; 34(2):79-89. PubMed ID: 1760820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Mokyr MB
    Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
    Gorelik L; Prokhorova A; Mokyr MB
    Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. THF-gamma 2, a thymic hormone, increases immunocompetence and survival in 5-fluorouracil-treated mice bearing MOPC-315 plasmacytoma.
    Ophir R; Pecht M; Halperin D; Rashid G; Burstein Y; Ben-Efraim S; Trainin N
    Cancer Immunol Immunother; 1989; 30(2):119-25. PubMed ID: 2598178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
    Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
    J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.
    Weiskirch LM; Baumgartel BA; Barker E; Mokyr MB
    Cancer Immunol Immunother; 1991; 32(6):353-63. PubMed ID: 1901031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymic humoral factor, THF-gamma 2, enhances immunotherapy of murine cytomegalovirus (MCMV) infection by both CD4+ and CD8+ immune T cells.
    Rager-Zisman B; Segev Y; Blagerman S; Palmon A; Tel-Or S; Pecht M; Trainin N; Burstein Y
    Immunol Lett; 1993 Dec; 39(1):23-31. PubMed ID: 7908278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late immune and haemopoietic functions in plasmacytoma-bearing mice cured by melphalan.
    Sagi O; Witz IP; Ramot B; Sahar E; Douer D
    Br J Cancer; 1988 Mar; 57(3):271-6. PubMed ID: 3258523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.